CD200: a putative therapeutic target in cancer. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Biochemical and Biophysical Research Communications Année : 2008

CD200: a putative therapeutic target in cancer.

Résumé

CD200 was recently described as a new prognosis factor in multiple myeloma and acute myeloid leukemia. CD200 is a membrane glycoprotein that imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cell-mediated immune responses. We investigated the expression of CD200 in cancer using publicly available gene expression data. CD200 gene expression in normal or malignant human tissues or cell lines was obtained from the Oncomine Cancer Microarray database, Amazonia database and the ITTACA database. We found significant overexpression of CD200 in renal carcinoma, head and neck carcinoma, testicular cancer, malignant mesothelioma, colon carcinoma, MGUS/smoldering myeloma, and in chronic lymphocytic leukemia compared to their normal cells or their tissue counterparts. Moreover, we show that CD200 expression is associated with tumor progression in various cancers. Taken together, these data suggest that CD200 is a potential therapeutic target and prognostic factor for a large array of malignancies.
Fichier principal
Vignette du fichier
CD200_et_cancer_HAL_INSERM.pdf (464.15 Ko) Télécharger le fichier
Supplementary_figure_1.pdf (79.06 Ko) Télécharger le fichier
Format : Autre

Dates et versions

inserm-00195258 , version 1 (10-12-2007)

Identifiants

Citer

Jérôme Moreaux, Jean-Luc Veyrune, Thierry Rème, John de Vos, Bernard Klein. CD200: a putative therapeutic target in cancer.. Biochemical and Biophysical Research Communications, 2008, 366 (1), pp.117-22. ⟨10.1016/j.bbrc.2007.11.103⟩. ⟨inserm-00195258⟩
70 Consultations
888 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More